Your browser doesn't support javascript.
loading
Outcomes of T-lymphoblastic lymphoma treated with pediatric ALL-like protocol.
Sengar, Manju; Carr, Robert; Jain, Hasmukh; Chanana, Raajit; Rangarajan, Venkatesh; Sridhar, Epari; Shet, Tanuja; Menon, Hari; Gujral, Sumeet; Laskar, Siddhartha.
Afiliación
  • Sengar M; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Carr R; Department of Haematology, Guy's and St Thomas' Hospital, King's College, London, UK.
  • Jain H; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Chanana R; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Rangarajan V; Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Sridhar E; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Shet T; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Menon H; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Gujral S; Department of Pathology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
  • Laskar S; Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Indian J Cancer ; 57(3): 262-266, 2020.
Article en En | MEDLINE | ID: mdl-32594075
BACKGROUND: The management of T-lymphoblastic lymphoma (T-LBL) in adults poses uncertainties, including optimal chemotherapy regimen, need for radiotherapy, and the benefit of stem cell transplant. This retrospective case series investigated the efficacy of the pediatric BFM-90 regimen in adult patients and evaluated the role of early response assessment by positron emission tomography with computed tomography (PET-CT) in predicting outcomes. METHODS: Patients aged 15 years or older with T-LBL diagnosed at Tata Memorial Hospital, Mumbai, India were given chemotherapy according to the European BFM-90 protocol (n = 38). The patients were evaluated for early response by interim PET-CT, post-induction and monitored for toxicity and long-term outcomes. RESULTS: Thirty-eight consecutive patients (median age 23.5 years) were analyzed. After a median follow-up of 33.5 (1-77) months, following induction, 35 out of 38 patients (92.1%) had achieved complete response (CR) on PET-CT. Thirty (78.9%) patients treated according to BFM-90 were alive in first remission. Three-year event-free survival for those with CR on PET-CT was 78%, against no survivors for those who remained PET-positive. CONCLUSION: This study demonstrates the feasibility and efficacy of BFM-90 approach in adults with T-LBL. We found an early PET response to be highly predictive of outcome.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Guideline / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Indian J Cancer Año: 2020 Tipo del documento: Article País de afiliación: India

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia-Linfoma Linfoblástico de Células T Precursoras Tipo de estudio: Guideline / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Indian J Cancer Año: 2020 Tipo del documento: Article País de afiliación: India